- Home
- FOXX vs FBRX Comparison
FOXX vs FBRX Comparison
Compare FOXX & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOXX
- FBRX
- Stock Information
- Founded
- FOXX 2017
- FBRX N/A
- Country
- FOXX United States
- FBRX United States
- Employees
- FOXX N/A
- FBRX N/A
- Industry
- FOXX
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- FOXX
- FBRX Health Care
- Exchange
- FOXX Nasdaq
- FBRX Nasdaq
- Market Cap
- FOXX 33.5M
- FBRX 35.3M
- IPO Year
- FOXX N/A
- FBRX N/A
- Fundamental
- Price
- FOXX $4.92
- FBRX $7.32
- Analyst Decision
- FOXX
- FBRX Strong Buy
- Analyst Count
- FOXX 0
- FBRX 4
- Target Price
- FOXX N/A
- FBRX $77.58
- AVG Volume (30 Days)
- FOXX 20.6K
- FBRX 54.4K
- Earning Date
- FOXX 05-15-2025
- FBRX 03-31-2025
- Dividend Yield
- FOXX N/A
- FBRX N/A
- EPS Growth
- FOXX N/A
- FBRX N/A
- EPS
- FOXX N/A
- FBRX N/A
- Revenue
- FOXX $42,988,015.00
- FBRX N/A
- Revenue This Year
- FOXX N/A
- FBRX N/A
- Revenue Next Year
- FOXX N/A
- FBRX N/A
- P/E Ratio
- FOXX N/A
- FBRX N/A
- Revenue Growth
- FOXX 98.81
- FBRX N/A
- 52 Week Low
- FOXX $2.45
- FBRX $4.11
- 52 Week High
- FOXX $14.99
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- FOXX N/A
- FBRX 46.88
- Support Level
- FOXX N/A
- FBRX $7.10
- Resistance Level
- FOXX N/A
- FBRX $9.04
- Average True Range (ATR)
- FOXX 0.00
- FBRX 1.27
- MACD
- FOXX 0.00
- FBRX 0.42
- Stochastic Oscillator
- FOXX 0.00
- FBRX 59.82
About FOXX Foxx Development Holdings Inc. Common Stock
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).